Key facts
- It has raised $13.0M; the latest was Seed Round ($13.0M) in Dec 2025.
- Notable investors include Charles Songhurst, CRV, Kickstart (US), Pelion Venture Partners, Harpoon VC — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Valinor (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Valinor (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Valinor (Biotechnology)
Developer of advanced machine learning models designed to accelerate clinical drug development. The company offers proprietary models trained on patient-derived samples that capture multi-omic and clinical assay profiles before and after treatment, enabling pharmaceutical researchers to optimize pipelines and improve therapeutic outcomes.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 8
- Website
- valinordiscovery.com/
- Ownership
- Privately Held (backing)
Valinor (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Valinor (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Valinor (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.